Hot Features
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered t... Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.003 | 17.6470588235 | 0.017 | 0.02 | 0.017 | 24719 | 0.01992833 | DE |
| 4 | -0.002 | -9.09090909091 | 0.022 | 0.0265 | 0.016 | 183627 | 0.02491122 | DE |
| 12 | -0.005 | -20 | 0.025 | 0.0265 | 0.016 | 137164 | 0.02359748 | DE |
| 26 | -0.009 | -31.0344827586 | 0.029 | 0.029 | 0.016 | 145527 | 0.02405539 | DE |
| 52 | -0.009 | -31.0344827586 | 0.029 | 0.029 | 0.016 | 145527 | 0.02405539 | DE |
| 156 | -0.009 | -31.0344827586 | 0.029 | 0.029 | 0.016 | 145527 | 0.02405539 | DE |
| 260 | -0.009 | -31.0344827586 | 0.029 | 0.029 | 0.016 | 145527 | 0.02405539 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.